近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Cao Y, ...Xu J*. Ann Surg. 2022; 275(1): e163–e173.
Wang J, ... Xu J*, Huang H*. Nat Commun. 2021; 12(1): 3080.
Dai S, ...Xu J*. J Immunother Cancer. 2021; 9(2): e001823.
Hu B, ... Xu J*. Cancer Res. 2020; 80(8): 1707–1719.
Zeng H, ...Xu J*. J Immunother Cancer. 2020; 8(1): e000651.
Zeng H, Liu Z, Wang Z, Zhou Q, Qi Y, Chen Y, Chen L, Zhang P, Wang J, Chang Y, Bai Q, Xia Y, Wang Y, Liu L, Zhu Y, Dai B, Guo J, Xu L*, Zhang W*, Xu J*. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. Int J Cancer. 2020; 146(2):542-552.(共同通讯作者，IF=4.982)
Lin C, He H, Liu H, Li R, Chen Y, Qi Y, Jiang Q, Chen L, Zhang P, Zhang H, Li H, Zhang W*, Sun Y*, Xu J*. Tumor-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019; 68(10):1764-1773. (共同通讯作者，IF=17.943)
Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Qi Y, Hu B, Fu H, Xie H, Zhou L, Chang Y, Zhu Y, Dai B*, Zhang W*, Xu J*. Tumor-associated macrophage-derived IL-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2019; 75(5): 752-763. (共同通讯作者，IF=17.298)
WangJT, Li H, Zhang H, Chen YF, Cao YF, Li RC, Lin C, Wei YC, Xiang XN, Fang HJ, Zhang HY, Gu Y, Liu X, Zhou RJ, Liu H, He HY, Zhang WJ*, Shen ZB*, Qin J*, Xu JJ*. Intratumoral IL17-producing cells infiltration correlate with anti-tumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Ann Oncol. 2019; 30(2): 266-273. (共同通讯作者，IF=14.196)
Wang J, Liu L, Bai Q, Ou C, Xiong Y, Qu Y, Wang Z, Xia Y, Guo J*, Xu J*. Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. Oncoimmunology. 2019; 8(1): e1515611. (共同通讯作者，IF=5.333)
Qi Y, Chang Y, Wang Z, Chen L, Kong Y, Zhang P, Liu Z, Zhou Q, Chen Y, Wang J, Bai Q, Xia Y, Liu L, Zhu Y, Xu L, Dai B, Guo J, Wang Y*, Xu J*, Zhang W*. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. Cancer Immunol Immunother. 2019; 68(12):2067-2080. (共同通讯作者，IF=4.900)
Xiong Y, Liu L, Xia Y, Qi Y, Chen Y, Chen L, Zhang P, Kong Y, Qu Y, Wang Z, Lin Z, Chen X, Xiang Z, Wang J, Bai Q, Zhang W, Yang Y, Guo J*, Xu J*. Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma. Cancer Immunol Immunother. 2019; 68(5):731-741. (共同通讯作者，IF=4.900)
Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L, Zhu Y, Wang Y, Zhang W*, Xu J*. CD19(+) tumor-infiltrating B-cells prime CD4(+) T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2019; 68(1): 45-56. (共同通讯作者，IF=4.900)
Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, Fu Q, Dai B, Ye D*, Xu J*. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer. Clin Cancer Res. 2018; 24(13): 3069–78. (共同通讯作者，IF=8.911)
Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J*, Sun Y*. Tumor infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Ann Surg. 2018; 267(2): 311-318. (共同通讯作者，IF=9.476，ESI高被引论文)
Lin Z, Liu L, Xia Y, Chen X, Xiong Y, Qu Y, Wang J, Bai Q, Guo J*, Xu J*. Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Oncoimmunology. 2018; 7(10): e1477461. (共同通讯作者，IF=5.333)
Liu Z, Zhu Y, Xu L, Zhang J, Xie H, Fu H, Zhou Q, Chang Y, Dai B*, Xu J*. Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. Oncoimmunology. 2018; 7(9): e1474317. (共同通讯作者，IF=5.333)
Wu S, He H, Liu H, Cao Y, Li R, Zhang H, Li H, Shen Z*, Qin J*, Xu J*. C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. Oncoimmunology. 2018; 7(6): e1433517. (共同通讯作者，IF=5.333)
Wei Y, Lin C, Li H, Xu Z, Wang J, Li R, Liu H, Zhang H, He H*, Xu J*. CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Cancer Immunol Immunother. 2018; 67(2): 261-269. (共同通讯作者，IF=4.900)
Wang J, Liu L, Qu Y, Xi W, Xia Y, Bai Q, Xiong Y, Long Q, Xu J*, Guo J*. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients. Cancer Immunol Immunother. 2018; 67(1): 79-87. (共同通讯作者，IF=4.900)
Cao Y, Liu H, Li H, Lin C, Li R, Wu S, Zhang H, He H*, Zhang W*, Xu J*. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. JAMA Surg. 2017; 152(11): e173120. (共同通讯作者，IF=10.668)
Liu Y, Liu H, Yang L, Wu Q, Liu W, Fu Q, Zhang W, Zhang H, Xu J*, Gu J*. Loss of N-acetylgalactosaminyltransferase-4 orchestrate oncogenic microRNA-9 in hepatocellular carcinoma. J Biol Chem. 2017; 292(8): 3186-200. (共同通讯作者，IF=4.106)
Zhu Y, Liu Z, Wang Y, Fu H, Wang Z, Xie H, Zhang J, Li G, Dai B, Xu J*, Ye D*. High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. Oncoimmunology. 2017; 6(11): e1359450. (共同通讯作者，IF=5.333)
Wang J, Lin C, Li H, Li R, Wu Y, Liu H, Zhang H, He H, Zhang W*, Xu J*. Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefits in patients with gastric cancer. Oncoimmunology. 2017; 6(11): e1353858. (共同通讯作者，IF=5.333)
Zhou L, Xu L, Chen L, Fu Q, Liu Z, Chang Y, Lin Z*, Xu J*. Tumor infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Oncoimmunology. 2017; 6(4): e1293211. (共同通讯作者，IF=5.333)
Liu H, Liu Y, Liu W, Zhang W, Xu J*. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015; 6: 8494. (通讯作者，IF= 11.878)
Zhang W, Liu H, Liu W, Liu Y, Xu J*. Polycomb-mediated loss of microRNA let-7c determines inflammatory macrophage polarization via PAK1-dependent NF-κB pathway. Cell Death Differ. 2015; 22(2): 287-97. (通讯作者，IF=8.086)
Liu W, Liu Y, Liu H, Zhang W, Fu Q, Xu J*, Gu J*. Tumor suppressive function of p21-activated kinase 6 in hepatocellular carcinoma. J Biol Chem. 2015; 290(47): 28489-501. (共同通讯作者，IF=4.106)
Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang WJ, Yang L, Fu Q, Xu JJ*, Gu JX*. Decreased Expression of Hnf4α/miR-122 Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Activity. J Biol Chem. 2015; 290(2): 1170-85. (共同通讯作者，IF=4.106)
An H, Xu L, Chang Y, Zhu Y, Yang Y, Chen L, Lin Z*, Xu J*. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2015; 51(14): 1953-61. (共同通讯作者，IF=6.680)
Fu Q, Chang Y, An H, Fu H, Zhu Y, Xu L, Zhang W*, Xu J*. Prognostic Value of Interleukin-6 and Interleukin-6 Receptor in Organ-Confined Clear-Cell Renal Cell Carcinoma: A 5-Year Conditional Cancer-Specific Survival Analysis. Br J Cancer. 2015; 113(11): 1581-1589. (共同通讯作者，IF=5.416)
Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z*, Xu J*. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 2015; 113(4): 626-33. (共同通讯作者，IF=5.416)
Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y, Lin Z, Xu J*. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015; 6: e1637. (通讯作者，IF=5.959)
Zhang H, Wang X, Xu J*,Sun Y*. Notch1 activation is a poor prognostic factor in patients with gastric cancer. Br J Cancer. 2014; 110(9): 2283-90. (共同通讯作者，IF=5.416)
An H, Xu L, Zhu Y, Lv T, Liu W, Liu Y, Liu H, Chen L*, Xu J*, Lin Z*. High C-X-C chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma. Br J Cancer. 2014; 110(9): 2261-8. (共同通讯作者，IF=5.416)
He H, Shen Z, Zhang H, Wang X, Tang Z, Xu J*, Sun Y*. Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer. Br J Cancer. 2014; 110(8): 2021-9. (共同通讯作者，IF=5.416)
Liu J, Liu H, Zhang W, Wu Q, Liu W, Liu Y, Pan D, Xu J*, Gu J. N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation. Glycobiology. 2013; 23(9): 1097-109. (通讯作者，IF=4.194)
Xu J, Liu H (co-first author), Chen L, Wang S, Zhou L, Yun X, Sun L, Wen Y*, Gu J*. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology. 2012; 143(1): 199-212.e4. (并列第一作者，IF=19.233)
Liu H, Xu J (co-first author), Zhou L, Yun X, Chen L, Wang S, Sun L, Wen Y*, Gu J*. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 2011; 71(24): 7547-57. (并列第一作者，IF=8.378)
Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, Liu Y, Wang W, Wen Y*, Gu J*. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 2010; 52(1): 142-54. (第一作者，IF=14.971)
京公网安备 11010802027423号